Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable recep…
USD34.18-2.48%vs prev. close
Performance
1W
+23.46%
1M
+22.08%
3M
-16.19%
1Y
+49.53%
YTD
+37.88%
Valuation
P/E
—
EPS TTM
-2.56
Dividend yield
—
Size and risk
Market cap
$7.3B
Beta
0.94
Price history
IMVT price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Immunovant
IMVT
Biotechnology
Mkt cap (USD bn)
7.3
P/E
—
Div yld
—
1W
+23.5%
1M
+22.1%
3M
-16.2%
6M
+21.0%
1Y
+49.5%
YTD
+37.9%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Immunovant
IMVT
Biotechnology
7.3
—
—
+23.5%
+22.1%
-16.2%
+21.0%
+49.5%
+37.9%
Subscribe to Equity Analytics to compare IMVT with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.